Applied DNA Sciences Inc
NASDAQ:APDN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.32
142.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Applied DNA Sciences Inc
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Strategic Restructuring: Applied DNA exited its DNA tagging and Security Products business and cut workforce by 20% to focus on its LineaRx synthetic DNA manufacturing.
Revenue Growth: Q1 fiscal 2025 revenue rose to $1.2 million from $891,000 last year, driven by higher product and testing revenues.
Improved Operating Loss: Operating loss narrowed to $3 million from $3.8 million, mainly due to lower SG&A expenses.
LineaRx Focus: Management highlighted strong demand and customer engagement for LineaRx platforms, with over 25 active projects and GMP facility now online.
New Product Launch: The company launched "Linea donor DNA" for CRISPR gene editing and plans to expand GMP capabilities for new DNA products.
Financial Position: Cash and equivalents were $9.3 million as of December 31 and $8.2 million as of January 31; company continues to face going concern risks.
Growth Strategy: Company aims for growth and profitability through modular, low-CapEx DNA manufacturing and disciplined cost management.
